Descartes-08
Cell therapy
Evidence outlook · registrational
Myasthenia Gravis: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2026-12-30.
Also in development:Dermatomyositis · Phase 1/2
Development in Systemic Lupus Erythematosus stopped (2026-04-30) as a strategic decision by the sponsor. Source
Development in Multiple Myeloma stopped (2021-06) for reasons the sponsor has not stated. Source
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06799247 NCT06799247 · Myasthenia Gravis Registry: NCT06799247 | 3 | Myasthenia Gravis Activities of Daily Living (MG-ADL) (assessment at 4 months of study) 2026-12-30 | In progress: results expected 30 Dec 2026 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Dermatomyositis: Phase 1/2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Descartes-08: this drug | Phase 1/2 | Cell therapy | BCMA (B-cell maturation antigen) | not yet graded | No reviewed efficacy summary in this indication | |
| Brepocitinib (Lisraya) | Approved | Small molecule | TYK2/JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| PF-06823859 | Phase 3 | Monoclonal antibody | Interferon beta (IFN-beta) | not yet graded | No reviewed efficacy summary in this indication | |
| Cadefrecitinib | Discontinued | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Descartes-08 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.